Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Open-Label Study to Evaluate Safety, Efficacy and Pharmacokinetics of Belimumab Plus Standard Therapy in Chinese Paediatric Patients With Active Systemic Lupus Erythematosus (SLE)

NCT04908865 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT04908865
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04908865 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Open-Label Study to Evaluate Safety, Efficacy and Pharmacokinetics of Belimumab Plus Standard Therapy in Chinese Paediatric Patients With Active Systemic Lupus Erythematosus (SLE)
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Completed
Start date
October 21, 2021
Completion date
August 13, 2024
Enrollment
67 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus